Table 2 Checkpoint Inhibitor-Induced Allograft Rejection in Patients with Cancer and Prior Solid Organ Transplantation

All

16/39 (41)

15.5 (5–60)

Renal

Ipilimumab

2/4 (50)

21

Nivolumab

2/5 (40)

18.5 (7–30)

Pembrolizumab

4/9 (44)

21 (5–60)

Ipilimumab + nivolumab

1/1 (100)

8

Ipilimumab followed by nivolumab or pembrolizuamb^a

2/4 (50)

14.5 (8–21)

All

11/23 (48)

21 (5–60)

Hepatic

Ipilimumab

1/3 (33)

13

Nivolumab

2/4 (50)

12.5 (7–18)

Pembrolizumab

1/3 (33)

7

Ipilimumab followed by pembrolizumab^a

0/1 (0)

All

4/11 (36)

10 (7–18)

Cardiac

Ipilimumab

0/1 (0)

Nivolumab

1/2 (50)

5

Pembrolizumab

0/1 (0)

Ipilimumab followed by pembrolizumab^a

0/1 (0)

All

1/5 (20)

5